© The Canadian Journal of Urology™; 21(Supplement 2); June 2014
37
Erectile dysfunction in primary care: a focus on cardiometabolic risk evaluation and stratification for future
cardiovascular events
50. D’Agostino RB, Grundy S, Sullivan LM, Wilson P. Validation
of the FraminghamHeart Disease Prediction Score: results of a
multiple ethnic groups investigation.
JAMA
2001;286(2):180-187.
51. Esposito K, Giugliano F, DiPalo C et al. Effect of lifestyle
changes in erectile dysfunction in obese men. A randomized
controlled trail.
JAMA
2004;291(24):2978-2984.
52. Gupta BP, Murad MH, Clifton MM et al. The effect of lifestyle
modification and cardiovascular risk factor reduction on
erectile dysfunction: a systematic review and meta-analysis.
Arch Intern Med
2011;171(20):1797-1803.
53. Greenland P, Alpert JS, Beller GA et al. 2010 ACCF/AHA
guideline for assessment of cardiovascular risk in asymptomatic
adults: a report of the American College of Cardiology
Foundation/AmericanHeartAssociationTask Force onPractice
Guidelines.
Circulation
2010;122(25):e584-636.
54. Gazzaruso C, Giordanetti S, De Amici E et al. Relationship
between erectile dysfunction and silent myocardial ischemia in
apparently uncomplicated type 2 diabetic patients.
Circulation
2004;110(1):22-26.
55. Naghavi M, Falk E, Hecht HS et al. From vulnerable plaque
to vulnerable patient--Part III: Executive summary of the
Screening for HeartAttack Prevention and Education (SHAPE)
Task Force report.
Am J Cardiol
2006;98(2A):2H-15H.
56. Eleid MF, Lester SJ, Wiedenbeck TL et al. Carotid ultrasound
identifies high risk subclinical atherosclerosis in adults
with low framingham risk scores.
J Am Soc Echocardiogr
2010;23(8):802-808.
57. Naqvi TZ, Mendoza F, Rafii F et al. High prevalence of
ultrasounddetected carotid atherosclerosis in subjectswith low
Framingham risk score: potential implications for screening
for subclinical atherosclerosis.
J Am Soc Echocardiogr
2010;23(8):
809-815.
58. Den Ruijter HM, Peters SA,Anderson TJ et al. Common carotid
intima-media thickness measurements in cardiovascular risk
prediction: a meta-analysis.
JAMA
2012;308(8):796-803.
59. Howard G, Sharrett AR, Heiss G et al. Carotid artery intimal-
medial thickness distribution in general populations as
evaluated by B-mode ultrasound. ARIC Investigators.
Stroke
1993;24(9):1297-1304.
60. Polonsky TS, Taillon LA, Sheth H et al. The association
between erectile dysfunction and peripheral arterial disease
as determined by screening ankle-brachial index testing.
Atherosclerosis
2009;207(2):440-444.
61. Greenland P, BonowRO, Brundage BH et al. ACCF/AHA2007
clinical expert consensus document on coronary artery calcium
scoring by computed tomography in global cardiovascular
risk assessment and in evaluation of patients with chest pain:
a report of the American College of Cardiology Foundation
Clinical Expert Consensus Task Force (ACCF/AHA Writing
Committee to Update the 2000 Expert Consensus Document
on Electron Beam Computed Tomography) developed in
collaboration with the Society of Atherosclerosis Imaging
and Prevention and the Society of Cardiovascular Computed
Tomography.
J Am Coll Cardiol
2007;49(3):378-402.
62. Jackson G, Padley S. Erectile dysfunction and silent coronary
artery disease: abnormal computed tomography coronary
angiogram in the presence of normal exercise ECGs.
Int J Clin
Pract
2008;62(6):973-976.
63. Yeboah J, McClelland RL, Polonsky TS et al. Comparison
of novel risk markers for improvement in cardiovascular
risk assessment in intermediate-risk individuals.
JAMA
2012;308(8):788-795.
64. Vlachopoulos C, Aznaouridis K, Ioakeimidis N et al. Arterial
function and intima-media thickness in hypertensive patients
with erectile dysfunction.
J Hypertens
2008;26(9):1829-1836.
65. Mancia G, Grassi G. The new European Society of
Hypertension/European Society of Cardiology (ESH/ESC)
Guidelines.
Ther Adv Cardiovasc Dis
2008;2(1):5-12.
66. Vlachopoulos C, Ioakeimidis N,Aznaouridis K et al. Prediction
of cardiovascular events with aortic stiffness in patients with
erectile dysfunction.
J Am Coll Cardiol
2012;59(13s1):E2072.
67. AraujoAB,DixonJM,SuarezEAetal.Clinicalreview:Endogenous
testosterone and mortality in men: a systematic review and
meta-analysis.
J Clin Endocrinol Metab
2011;96(10):3007-3019.
68. Corona G, Monami M, Boddi V et al. Low testosterone is
associatedwith an increased risk of MACE lethality in subjects
with erectile dysfunction.
J Sex Med
2010;7(4 Pt 1):1557-1564.
69. Pye SR, Huhtaniemi IT, O’Neill TW et al. editors. Late-onset
hypogonadism (LOH) and mortality in European men.
Endocrine Society 2012; Houston, TX.
70. Shores MM, Smith NL, Forsberg CW et al. Testosterone
treatment and mortality in men with low testosterone levels.
J Clin Endocrinol Metab
2012;97(6):2050-2058.
71. Wu FC. Caveat emptor: does testosterone treatment reduce
mortality inmen?
J Clin Endocrinol Metab
2012;97(6):1884-1886.
72. Hackett G, Kell P, Ralph D et al. British Society for Sexual
Medicine guidelines on themanagement of erectile dysfunction.
J Sex Med
2008;5(8):1841-1865.
73. Buvat J, Maggi M, Gooren L et al. Endocrine aspects of male
sexual dysfunctions.
J Sex Med
2010;7(4 Pt 2):1627-56.
74. Buvat J, Maggi M, GuayA, Torres LO. Testosterone deficiency
inmen: systematic review and standard operating procedures
for diagnosis and treatment.
J Sex Med
2013;10(1):245-284.
75. Bolona ER, Uraga MV, Haddad RM et al. Testosterone use in
men with sexual dysfunction: a systematic review and meta-
analysis of randomizedplacebo-controlled trials.
MayoClinProc
2007;82(1):20-28.
76. Buvat J, Montorsi F, Maggi M et al. Hypogonadal men
nonresponders to the PDE5 inhibitor tadalafil benefit from
normalization of testosterone levels with a 1% hydroalcoholic
testosterone gel in the treatment of erectile dysfunction
(TADTEST study).
J Sex Med
2011;8(1):284-293.
77. Hackett G. Long acting testosterone undecanoate improved
ageing male symptom scores but not depression versus
placebo in a hypogonadal populationwith type 2 diabetes. 14
th
European Society of Sexual Medicine Congress. 2011; Milan,
Italy.
78. RathmannW, Haastert B, Herder C et al. Differential association
of adiponectin with cardiovascular risk markers in men and
women? The KORAsurvey 2000.
Int J Obes
2007;31(5):770-776.
79. Yamauchi T, Kamon J,Minokoshi Yet al.Adiponectin stimulates
glucose utilization and fatty-acid oxidation by activatingAMP-
activated protein kinase.
Nat Med
2002;8(11):1288-1295.
80. Snijder MB, Heine RJ, Seidell JC et al. Associations of
adiponectin levels with incident impaired glucose metabolism
and type 2 diabetes in older men andwomen: the hoorn study.
Diabetes Care
2006;29(11):2498-2503.
81. Silvestro A, Brevetti G, Schiano V et al. Adhesion molecules
and cardiovascular risk in peripheral arterial disease. Soluble
vascular cell adhesionmolecule-1 improves risk stratification.
Thromb Haemost
2005;93(3):559-563.
82. Nikoobakht M, Nasseh H, Pourkasmaee M. The relationship
betweenlipidprofileanderectiledysfunction.
IntJImpotRes
2005;
17(6):523-526.
83. Burke JP, Jacobson DJ, McGree ME et al. Diabetes and sexual
dysfunction: results from the Olmsted County Study of
Urinary Symptoms and health status among men.
J Urol
2007;
177(4):1438-1442.
84. Ponholzer A, Temml C, Mock K, Marszalek M, Obermayr R,
Madersbacher S. Prevalence and risk factors for erectile
dysfunction in 2869 men using a validated questionnaire.
Eur Urol
2005;47(1):80-85.
85. Saigal CS, Wessells H, Pace J, Schonlau M, Wilt TJ for the
UrologicDiseases inAmericaProject. Predictors andprevalence
of erectile dysfunction in a racially diverse population.
Arch Intern Med
2006;166(2):207-212.
